22 Eli Lilly and the Tirzepatide Portfolio: Manufacturing as a Moat While Novo Nordisk has focused heavily on the longevity of a single molecule, Eli Lillys strategy for tirzepatide (Mounjaro and Zepbound) is defined by clinical differentiation and an aggressive manufacturing moat
PT-141 represents what happens when a promising lead compound is properly developed through clinical trials, while MT-2 remains in the research domain with significant safety concerns
Importantly, interactions between this peptide and other medications have not been extensively studied, which underscores the importance of using this peptide only under qualified supervision for research purposes
Nonetheless, liraglutide should not be used in patients with a history or family history of medullary thyroid cancer, or in patients with type 2 multiple endocrine neoplasia
To avoid constipation while taking Wegovy and keep your body free from toxins and waste, make sure to get enough fibre in your diet, drink plenty of water, introduce a greater variety of plants and stay active with regular exercise
Biomolecules & Therapeutics, 24 (6), 630-637
